Overall health copyright advised the Star it's contacted Adastra to “reiterate the incredibly slender parameters in their licence.” The company subsequently issued a 2nd launch Friday retracting what it mentioned in its very first statement and noting: “Such statements shouldn't be relied upon.”Karen Ward, a Vancouver-based independent drug